Conversation

Gilead’s twice-yearly medicine to prevent HIV succeeded in a Phase 3 trial.
None of the roughly 2,000 women in the trial who received the #lenacapavir shot contracted HIV.
Gilead needs to replicate the results in another Phase 3 trial before seeking FDA approval. The company expects to share more data later this year or early next year.
If the results are positive, lenacapavir for PrEP could reach the market as soon as late 2025

https://www.cnbc.com/2024/06/20/gilead-prep-lenacapavir-succeeds-in-phase-3-trial.html